About AbbVie
AbbVie news and updates
The Berkeley Catalyst Fund partnered with AbbVie Inc on Jul 19th 20'.
“Between the substantial protein degradation partnership with AbbVie announced at the end of last year and this financing round, The Berkeley Catalyst Fund has significantly strengthened its resources to deliver on its vision of developing breakthrough medicines for patients.”
Jan 1, 2021 | frontiermeds.comAbbVie Inc has issues with multiple allegations of fraud
A judge in the Circuit Court of Cook County granted summary judgment to biopharmaceutical company AbbVie Inc., dispensing with multiple allegations of fraud made by a group of hedge funds.
Jan 1, 2022 | chicagolawbulletin.comAbbVie Inc. acquired Syndesi Therapeutics SA for $1B on Mar 1st 22'.
"With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders."
Jan 1, 2022 | abbvie.comAbbVie Inc. merges with Shire
Gardy & Notis, LLP pursued claims that AbbVie, Inc. and its Chief Executive Officer defrauded Shire plc investors by making false statements regarding AbbVie's planned merger with Shire.
Jan 1, 2019 | gardylaw.comAlvotech partners with AbbVie Inc.
Alvotech announced that it has entered into a settlement agreement with AbbVie that will allow Alvotech to market AVT02 (100 mg/mL), its high-concentration, citrate-free biosimilar adalimumab that references Humira, in the United States.
Jan 1, 2021 | centerforbiosimilars.comGenmab, Inc. partnered with AbbVie Inc. on Jun 1st 20'.
In June 2020, Genmab ( GMAB ) partnered with AbbVie ( ABBV ) to jointly develop and commercialize three of its bispecific antibodies, including epcoritamab (DuoBody-CD3xCD20).
Jan 1, 2022 | seekingalpha.comAquahtraining partners with AbbVie Inc.
AQuaH Training School (ATS) in collaboration with ABBVIE has decided to award 125 learners with a fully funded HIV Management Guideline, SA course.
Jan 1, 2021 | aquahtraining.co.zaAbbVie Inc. acquires Mavupharma
Following their development, many of Frazier’s investment companies go on to be acquired by pharma giants, such as Mavupharma, which was acquired by AbbVie.
Jan 1, 2022 | biospace.comAbbVie Inc. is developing novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases on Mar 11th 22'.
AbbVie (NYSE: ABBV) and Gedeon Richter Plc. (‘Richter’) today announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases.
Jan 1, 2022 | gedeonrichter.comAbbVie Inc. is developing potential novel, direct-acting antiviral treatments for COVID-19 on Mar 16th 22'.
AbbVie and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, today announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19.
Jan 1, 2022 | pharmafocusasia.comAbbVie Inc. partners with Harvard University
AbbVie is already working on COVID-19 collaborations with Harvard University, the National Institutes of Health and other groups.
Jan 1, 2022 | fiercebiotech.comAbbVie Inc. recognized as Dividend Channel ''S.A.F.E. 25
A bbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.8% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.
Jan 1, 2022 | nasdaq.comAbbVie Inc. partnered with Neurocrine Biosciences, Inc. on Jun 1st 10'.
AbbVie partnered with Neurocrine Biosciences in June 2010, when it was still a part of Abbott Laboratories, to develop and market the drug.
Jan 1, 2018 | biopharmadive.comAbbVie Inc. has issues with antitrust litigation over its alleged scheme
AbbVie Inc., facing antitrust litigation over its alleged scheme to clear the market for its testosterone booster AndroGel, can relitigate key decisions against it by two courts in a prior case brought by the Federal Trade Commission, a federal judge in Philadelphia ruled.
Jan 1, 2022 | bloomberglaw.comAbbVie Inc. partners with Scripps Research Institute
AbbVie announced it is joining forces with Scripps Research, an independent biomedical research institute, to develop novel, direct-acting antiviral treatments to tackle COVID-19.
Jan 1, 2022 | eversana.comAdaptive Biotech partners with AbbVie Inc.
Adaptive has also partnered with AbbVie and Genentech on MRD testing in clinical trials.
Jan 1, 2020 | precisiononcologynews.comAbbVie Inc. launches Kaletra IP
In an official company statement, AbbVie announced its intention to dedicate its Kaletra IP to the public in response to the COVID-19 health crisis.
Jan 1, 2020 | inventorsdigest.comAbbVie Inc. will have issues with patent infringement cases on Jan 1st 23'.
AbbVie’s long list of patent infringement cases have resulted in the delay of 7 FDA-approved adalimumab biosimilars from entering the market until 2023.
Jan 1, 2022 | centerforbiosimilars.comAbbVie Inc. recognized as Best Workplaces for Women certification
“I’m equally delighted that AbbVie has also been awarded Best Workplaces for Women certification, reflecting our commitment to empower female colleagues to reach their full potential.
Jan 1, 2022 | independent.ieBronstein, Gewirtz & Grossman, LLC files suit against AbbVie Inc.
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ABBVie, Inc. and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired ABBVie securities between April 30, 2021, and August 31, 2021, .
Jan 1, 2022 | investingnews.comKessler Topaz Meltzer & Check, LLP files suit against AbbVie Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit against ABBVie, Inc. on behalf of all persons and entities who purchased or otherwise acquired ABBVie securities between April 30, 2021, and August 31, 2021, inclusive .
Jan 1, 2022 | investingnews.comAbbVie Inc. launched single-tablet version of blood cancer drug Imbruvica on May 16th 18'.
(AbbVie) When AbbVie introduced a single-tablet version of its blood cancer drug Imbruvica earlier this year, it pitched the new formula as easier and more convenient for patients who took the older version as often as four times a day.
Jan 1, 2018 | fiercepharma.comAbbVie Inc. has issues with securities fraud or other unlawful business practices
The investigation concerns whether AbbVie and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jan 1, 2022 | prnewswire.comBragar Eagel & Squire PC files suit against AbbVie Inc.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against AbbVie, Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021 and August 31, 2021, both dates inclusive (the “Class Period”).
Jan 1, 2022 | businesswire.comSeverino leaves AbbVie Inc. as Vice Chairman and President
Dr. Severino joins Flagship from AbbVie, Inc. where he served as Vice Chairman and President.
Jan 1, 2022 | prnewswire.comAbbVie Inc. hired Severino as executive vice president of research and development and chief scientific officer on Jan 1st 14'.
In a regulatory filing, AbbVie said Severino will be joining a "bioplatform innovation company as CEO-Partner and as CEO of one of its companies," effective May 31.
Jan 1, 2022 | investing.comAbbVie Inc. has issues with possible violations of federal securities laws
The Law Offices of Frank R. Cruz announces an investigation of AbbVie Inc. on behalf of investors concerning the Company’s possible violations of federal securities laws.
Jan 1, 2022 | investingnews.comAbbVie Inc. integrates with Plexium, Inc.
This collaboration combines AbbVie's extensive neuroscience capabilities with Plexium's comprehensive TPD platform that enables the discovery of novel therapies toward historically challenging drug targets.
Jan 1, 2022 | pharmafocusasia.comDragonflytx partnered with AbbVie Inc. on Apr 20th 22'.
Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced an expansion of its research collaboration with AbbVie (NYSE: ABBV ) to discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases.
Jan 1, 2022 | prnewswire.comBioArctic AB partnered with AbbVie Inc. on Jan 1st 16'.
BioArctic has been collaborating with AbbVie since 2016, when the two companies entered into a research agreement.
Jan 1, 2022 | prnewswire.comAbbVie Inc. is developing additional drug candidates in immune-mediated diseases on Apr 27th 22'.
AbbVie ( NYSE: ABBV ) broadened its existing partnership with clinical-stage biopharmaceutical company Dragonfly Therapeutics to develop additional drug candidates in immune-mediated diseases, it was announced on Wednesday.
Jan 1, 2022 | seekingalpha.comArcticbiopro partners with AbbVie Inc.
ArcticBio has also developed the PD1601 and PD1602 antibodies—which also target α-syn—for treatment of PD in conjunction with AbbVie.
Jan 1, 2022 | neurologylive.comAbbVie Inc. launches Phase 2 Proof-of-Concept study evaluating a triple combination therapy in cystic fibrosis
AbbVie announced that a Phase 2 Proof-of-Concept study evaluating a triple combination therapy in cystic fibrosis (CF) did not meet the prespecified criteria.
Jan 1, 2022 | globenewswire.comNurtec identified as competitor of AbbVie Inc.
Nurtec also competes with a second AbbVie drug, newly launched Qulipta, in the preventive space for episodic migraine.
Jan 1, 2022 | fiercepharma.comAbbVie Inc. is developing alpha-synuclein antibodies, including ABBV-0805
(RTTNews) - AbbVie (ABBV) has terminated its collaboration with BioArctic AB, a Swedish biopharma company, to develop alpha-synuclein antibodies, including ABBV-0805.
Jan 1, 2022 | nasdaq.comAbbVie Inc. partners with Jacobiopharma
AbbVie also has a SHP2 inhibitor in its pipeline through an agreement with Jacobio Pharmaceuticals.
Jan 1, 2020 | fiercebiotech.comMoran Center will partner with AbbVie Inc. on May 24th 22'.
The Moran Center for Youth Advocacy, in partnership with the Evanston Public Library, AbbVie, and Kirkland & Ellis, will hold a walk-in legal clinic May 24 to help people in Evanston and the surrounding areas with sealing evictions and advise on the criminal expungement process.
Jan 1, 2022 | moran-center.orgAbbVie Inc. is developing treatments for autoimmune disease and cancer
Chicago-based AbbVie and Waltham, MA-headquartered Cugene entered a collaboration deal to develop treatments for autoimmune disease and cancer.
Jan 1, 2022 | biospace.comAbbVie Inc. is developing Synthetic Biotic-based treatments for inflammatory bowel disease
It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease.
Jan 1, 2022 | defenseworld.netAbbVie Inc. had issues with fraud lawsuit on May 20th 20'.
Less than two years ago, AbbVie paid $24 million to settle a fraud lawsuit from the California Department of Insurance.
Jan 1, 2022 | fiercepharma.comAbbVie Inc. is developing T-cell therapies aimed primarily at cancer on Jun 25th 18'.
AbbVie (NYSE: ABBV ), a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors.
Jan 1, 2018 | prnewswire.comAbbVie Inc. partners with Calibr
AbbVie is teaming up with the California Institute for Biomedical Research (Calibr), a division of Scripps Research Institute, to design and develop a new generation of switchable chimeric antigen receptor T-cell (CAR-T) therapies for cancer.
Jan 1, 2018 | acs.orgAbbVie Inc. acquired Pharmacyclics LLC on Jan 1st 15'.
Note that Imbruvica was co-developed by Johnson & Johnson and Pharmacyclics, which was acquired by AbbVie in 2015.
Jan 1, 2019 | forbes.comAbbVie Inc. has issues with deceptive marketing of a testosterone replacement drug
For instance, his campaign reported receiving a total of $23,333 from five attorneys with the national firm of DiCello Levitt Gutzler, which is representing New Mexico in a state district court case against pharmaceutical company AbbVie Inc. and its affiliates, which are accused of deceptive marketing of a testosterone replacement drug.
Jan 1, 2022 | abqjournal.comSpringWorks Therapeutics, Inc. partnered with AbbVie Inc. on Dec 1st 21'.
Last December, SpringWorks entered into a collaboration agreement with AbbVie to evaluate nirogacestat in combination with ABBV-383 for the treatment of patients with relapsed or refractory multiple myeloma.
Jan 1, 2022 | zacks.comAbbVie Inc. partners with Arabio
AbbVie will partner with Arabio to manufacture Humira and other drugs in Saudi Arabia.
May 13, 2017 | arabio.comAbbVie Inc. launched AbbVie Research Collaborative on May 1st 22'.
As part of this initiative, AbbVie recently launched the AbbVie Research Collaborative, a health data platform that enables adults anywhere in the United States to partner with AbbVie’s world-class scientific researchers.
Jan 1, 2022 | abbvie.comAdam Houghton leaves AbbVie Inc. as Chief business officer
Chief business officer Adam Houghton joined Upstream from AbbVie, where he led venture investing and previously had positions at AbbVie and Lilly.
Jan 1, 2022 | labiotech.euAbbVie Inc. launched data from Cohort 3 on Jun 10th 22'.
ABBV ie (NYSE: ABBV ) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer.
Jan 1, 2022 | investingnews.comAbbVie Inc. is developing KYPROLIS
For instance, AbbVie is developing KYPROLIS, which is in the phase II stage of clinical trials for the treatment of prostate cancer and renal cell carcinoma.
Jan 1, 2022 | memberclicks.netAbbVie Inc. acquired Allergan plc on May 1st 20'.
May 2020: AbbVie announced the acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
Jan 1, 2022 | globalinsightservices.comCugene Inc. partners with AbbVie Inc.
"Cugene Inc. is very pleased to partner with AbbVie, a global leader in the development and commercialization of innovative immunology therapies," said Luke Li, M.D., Chief Executive Officer of Cugene Inc. "AbbVie is an ideal partner for CUG252, with their commitment to R&D, deep therapeutic area expertise, and the global resources needed to maximize CUG252's therapeutic potential for patients suffering from autoimmune diseases.
Jan 1, 2022 | prnewswire.comAbbVie Inc. partners with Heart of America
Photo Credit: AbbVie AbbVie teamed up with the Heart of America Foundation to carry out the transformative project during the biotech company’s “Week of Possibilities” initiative, which focuses on creating quality educational environments that impact children’s development across the country.
Jan 1, 2022 | tapinto.netAbbVie Inc. has issues with alleged securities fraud” occurring
The class action lawsuit attempts to reimburse AbbVie investors who were “adversely affected by alleged securities fraud” occurring between April 30, 2021, and Aug. 31, 2021.
Jan 1, 2022 | topclassactions.comAbbVie Inc. acquired Ubrelvy on Jan 1st 20'.
In 2020 AbbVie acquired Ubrelvy from Allergan.
Jan 1, 2022 | themedwriters.comJett Foundation, Inc. partners with AbbVie Inc.
Jett Foundation, Inc. is collaborating with AbbVie on its subretinal and suprachoroidal trials for the treatment of wet AMD and diabetic retinopathy, as Jett Foundation, Inc. aim to make a significant impact for the millions of patients suffering from vision loss associated with these retinal diseases.”
Jan 1, 2022 | jettfoundation.orgAbbVie Inc. has issues with potential breaches of fiduciary duties
An investigation was announced for long-term investors in shares of AbbVie Inc. (NYSE: ABBV) concerning potential breaches of fiduciary duties by certain directors of AbbVie Inc.
Jan 1, 2022 | openpr.comPfizer, Inc. identified as competitor of AbbVie Inc.
Pfizer currently plans to launch ABRILADA in the U.S. as early as July 2023 in accordance with the terms of its agreement with AbbVie.
Jan 1, 2022 | pfizer.comAbbVie Inc. acquired Allergan Aesthetics on Jan 1st 20'.
As an example, in 2020, when AbbVie acquired Allergan, the SEC and other regulators required the companies to divest brazikumab and Zenpep (pancrelipase).
Jan 1, 2022 | biospace.comAbbVie Inc. received award best Corporate Social Responsibility Programme 2016 on Jul 1st 17'.
This was most recently recognised at the 2016 Pharma Industry Award where AbbVie won the award for best Corporate Social Responsibility Programme 2016.
Jan 1, 2017 | spanisharmadaireland.comOncternal Therapeutics, Inc. partners with AbbVie Inc.
Oncternal Therapeutics has entered into a clinical trial collaboration with AbbVie.
Jan 1, 2022 | fiercebiotech.comAbbVie Inc. acquires iSTAR Medical for $475M
If AbbVie exercises the right to acquire iSTAR Medical, the stockholders of iSTAR Medical would also be eligible to receive additional contingent payments of up to $475M in a closing payment and upon achievement of certain predetermined milestones.
Jan 1, 2022 | istar-medical.comAbbVie Inc. is developing iSTAR Medical’s MINIject device
AbbVie and iSTAR Medical announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma.
Jan 1, 2022 | eyewire.newsAbbVie Inc. acquired Allergan for $63B on Jan 1st 20'.
AbbVie, which acquired Allergan for $63 billion in 2020, didn’t respond to emails and voicemails seeking comment.
Jan 1, 2022 | insurancejournal.comAbbVie Inc. acquired Loloestrin on Jan 1st 20'.
Abbvie, which acquired Allergan in 2020, disclosed the agreement in its earnings disclosure Friday.
Jan 1, 2022 | einnews.comAbbVie Inc. is developing SHP2 inhibitors, including JAB-3312 and JAB-3068 on May 1st 20'.
Jacobio entered into a licensing agreement with AbbVie in May 2020 to develop and commercialize SHP2 inhibitors, including JAB-3312 and JAB-3068, on a worldwide basis.
Jan 1, 2021 | jacobiopharma.comAbbVie Inc. is developing novel treatment for neurological conditions on Jan 1st 22'.
For instance, this year, AbbVie Inc. (NYSE: ABBV) partnered with Plexium, Inc. to develop and commercialize a novel treatment for neurological conditions ( https://ibn.fm/nNezj ).
Jan 1, 2022 | stockstobuynow.comAbbVie Inc. had issues with antitrust violations on Jun 1st 20'.
In June 2020, U.S. District Judge Manish Shah sided with North Chicago-based AbbVie in a nationwide slew of lawsuits accusing the pharmaceutical company of antitrust violations.
Jan 1, 2022 | cookcountyrecord.comAbbVie Inc. is developing treatments for neurological disorders
AbbVie, looking to develop new treatments for neurological disorders, has entered into another collaboration with the Japan-based drugmaker Sosei Heptares.
Jan 1, 2022 | escalatesciences.comAbbVie Inc. hired Tara as national sales trainer on Jan 1st 13'.
At her new job, Tara got the opportunity to become a national sales trainer and was later hired as a specialty sales representative by AbbVie in 2013.
Jan 1, 2022 | techiegamers.comAbbVie Inc. launched YouTube channel on Jul 17th 22'.
Recently, AbbVie Inc. launched a YouTube channel to provide deeper patient education and it has more than five million views since launch," said Carrie Strom, Global President Allergan Aesthetics.
Aug 16, 2022 | abbvie.comI-Mab Biopharma Co. partners with AbbVie Inc.
Under Shen’s leadership, I-Mab formed a CD47 alliance with AbbVie in September 2020 with lemzoparlimab as the centerpiece, and a year later our Amber Tong detailed I-Mab’s aspirations for other comparable partnerships, notably for development of the CD73 antibody uliledlimab.
Dec 17, 2021 | endpts.comSinghal leaves AbbVie Inc.
Dr. Singhal joins OncoResponse from AbbVie, where he helped build an impressive portfolio and key translational science capabilities in oncology, immunology and other diseases.
Jan 1, 2018 | oncoresponse.comAbbVie Inc. decreased headcount by 99 on Sep 19th 22'.
Yesterday Bristol Myers Squibb announced it was laying off 261 people in two different sites in San Diego, while AbbVie announced it would cut 99 jobs in Irvine, California.
Sep 20, 2022 | biospace.comAbbVie Inc. expanded facilities to Cork, Ireland on May 3rd 22'.
AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company with a significant presence across eight Irish locations, today announced a €60 million investment at its manufacturing site in Cork.
May 2, 2022 | wearecork.ieAbbVie Inc. acquired Stemcentrx, Inc. for $5.8B on Jan 1st 16'.
In 2016, AbbVie spent $5.8bn to acquire Stemcentrx, citing its candidate lung cancer ADC Rova-T as a major driver.
Sep 3, 2019 | bioprocessintl.comAbbVie Inc. is developing MINIject device on Sep 20th 22'.
EQT Life Sciences today announced that AbbVie (NYSE: ABBV) and iSTAR Medical SA have entered into a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject® device, a next-generation minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma.
Sep 19, 2022 | private-equitynews.comIDA Ireland partners with AbbVie Inc.
IDA Ireland is delighted to partner with AbbVie in creating these opportunities for new employees who will help write the next chapter in its story.”
Sep 20, 2022 | idaireland.deAbbVie Inc. is developing treatment option for migraine
Currently, AbbVie is working on a new treatment option for migraine.
Sep 25, 2022 | news-medical.netCapsida Biotherapeutics Inc. partnered with AbbVie Inc. on Apr 29th 21'.
“Capsida Biotherapeutics Inc. is very pleased to debut today with the backing of experienced company creators in Versant and Westlake, as well as with a significant pharma partnership with AbbVie.”
Apr 28, 2021 | capsida.comAbbVie Inc. is developing CD47 antibodies
It has developed a partnership with AbbVie ( ABBV ) to develop new CD47 antibodies.
Sep 27, 2022 | seekingalpha.comLaura Schumacher retired from AbbVie Inc. on Oct 17th 22'.
AbbVie Inc. announced Monday that its longtime law department leader Laura Schumacher will retire after more than three decades at the company and its predecessor Abbott Laboratories.
Oct 16, 2022 | bloomberglaw.comLaura Schumacher retired from AbbVie Inc. on Apr 13th 20'.
AbbVie Inc. announced Monday that its longtime law department leader Laura Schumacher will retire after more than three decades at the company and its predecessor Abbott Laboratories.
Apr 5, 2020 | bloomberglaw.comAbbVie Inc. acquires DJS Antibodies Ltd for $225M
AbbVie will buy private U.K.-based biotechnology company DJS Antibodies in a deal that gives it access to an experimental drug for an aggressive lung disease as well as technology to develop certain kinds of antibody medicines.
Oct 19, 2022 | phamed.comAbbVie Inc. expands facilities to Oxford, United Kingdom
AbbVie anticipates retaining all current DJS employees and the biotech’s facility in Oxford, England.
Oct 19, 2022 | fiercebiotech.comAbbVie Inc. recognized as No. 23 on The DiversityInc Top 50 Companies for Diversity list in 2022
AbbVie ranked No. 23 on The DiversityInc Top 50 Companies for Diversity list in 2022.
Oct 19, 2022 | diversityinc.comAbbVie Inc. acquired Latisse on Mar 1st 20'.
March 2020 : AbbVie Inc. announced that it has completed the acquisition of Allergan; a step that will help the company gain access to the Allergan’s exceptional portfolio.
Nov 18, 2022 | medgadget.comAbbVie Inc. partners with D187
"As a North Chicago -headquartered company, AbbVie Inc. has been a longstanding partner with District 187 to improve student success and support children, families and the community," said Laura Schumacher, vice chairman, external affairs and chief legal officer, AbbVie.
Nov 15, 2022 | abbvie.comAbbVie Inc. partners with Deep Science Ventures Limited
AbbVie, which markets blockbuster rheumatoid arthritis drug Humira and has blockbuster follow-ups in Rinvoq and Skyrizi, will first work with DSV to identify areas of unmet need in the inflammatory area.
Nov 28, 2022 | fiercebiotech.comAbbVie Inc. partners with Deep Science Ventures Limited
AbbVie, which markets blockbuster rheumatoid arthritis drug Humira and has blockbuster follow-ups in Rinvoq and Skyrizi, will first work with DSV to identify areas of unmet need in the inflammatory area.
Nov 28, 2022 | fiercebiotech.comAbbVie Inc. partners with HotSpot Therapeutics, Inc
AbbVie ( ABBV ) is collaborating with Hotspot Therapeutics to license its discovery-stage IRF5 drug to treat autoimmune diseases.
Dec 6, 2022 | investors.comAbbVie Inc. partners with HotSpot Therapeutics, Inc
AbbVie ( ABBV ) is collaborating with Hotspot Therapeutics to license its discovery-stage IRF5 drug to treat autoimmune diseases.
Dec 6, 2022 | investors.comAbbVie Inc. launched data from Cohort 3 of Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis on Dec 10th 22'.
AbbVie (NYSE: ABBV ) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis (MF).
Dec 10, 2022 | prnewswire.comAbbVie Inc. is developing MINIject device on Nov 2nd 22'.
AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject ® device, a next-generation minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma.
Nov 1, 2022 | nolaangelnetwork.orgAbbVie Inc. launches Humira
When AbbVie launched Humira, there were other drugs available to treat some or all of the conditions for which it is prescribed, in particular Remicade (infliximab, made by Janssen) and Enbrel (etanercept, made by Amgen).
Dec 14, 2022 | qz.comAbCellera Biologics Inc. partnered with AbbVie Inc. on Dec 15th 22'.
AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. (NYSE: ABBV).
Dec 15, 2022 | galvnews.comAbbVie Inc. partners with Ironwood Pharmaceuticals, Inc.
AbbVie is partnered with Ironwood for the development and commercialization of linaclotide in all other territories worldwide.
Dec 16, 2022 | investingnews.comAbbVie Inc. recognized as Dow Jones Sustainability World Index (DJSI World) and Dow Jones Sustainability North America Index (DJSI North America)
AbbVie announced that it has been named to the Dow Jones Sustainability World Index (DJSI World) and Dow Jones Sustainability North America Index (DJSI North America) for the 10th year in a row.
Dec 14, 2022 | diversityinc.comAbbVie Inc. will launch biosimilar of AbbVie's Humira on Dec 22nd 23'.
AbbVie is facing fierce competition in the U.S. adalimumab market as various companies are planning to launch biosimilar of AbbVie's Humira next year.
Dec 22, 2022 | koreabiomed.comAbbVie Inc. launches training and resources
As part of the company’s commitment to the migraine community and advancing research across the spectrum of migraine, AbbVie has launched training and resources to support employees who live with migraine
Dec 13, 2022 | abbvie.comHealth and Human Services Commission partnered with AbbVie Inc. on Nov 20th 22'.
The Texas Health and Human Services Commission (HHSC) recently partnered with AbbVie to work toward significantly reducing chronic Hepatitis C in Medicaid patients.
Dec 19, 2022 | txvendordrug.com